Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VWR International, LLC to Distribute Illumina’s qPCR Portfolio

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Dramatically expands sales reach within U.S. market.

Illumina, Inc. announced that VWR International, LLC, a global distributor of laboratory supplies and services, will distribute Illumina’s qPCR portfolio including the Eco™ Real-Time PCR System and NuPCR™ reagents within the United States, one of the world’s largest qPCR instrumentation markets. The agreement extends Illumina’s reach for its innovative Eco System and novel NuPCR probe-based technology into thousands of laboratories and facilities nationwide, by leveraging VWR’s 150 years of industry experience and its well-established distribution network.

“Complementing Illumina’s commercialization efforts with VWR’s talented team of sales and services representatives enables us to significantly expand promotion and support of both the Eco System and NuPCR reagents in molecular biology laboratories throughout the United States,” said Mark Lewis, Senior Vice President and General Manager of Illumina’s Molecular Biology and PCR Business. “We are very excited to join forces with VWR to accelerate adoption of our qPCR portfolio, particularly into the pharmaceutical and industrial markets where VWR has a strong presence.”

Real time PCR is a precise, highly sensitive PCR method with applications in basic research and diagnostics, where, for example, it is used for quantitation of gene expression targets, verification of array data, and pathogen detection. Illumina’s Eco Real-Time PCR System is an affordable, compact instrument that allows researchers to perform any qPCR application directly on their bench top and is an economical alternative to traditional large, expensive PCR instruments. The company’s novel, NuPCR probe-based qPCR technology is designed to show improved specificity and sensitivity to complex gene targets, as compared to existing qPCR technologies on the market today. It is compatible with any real-time PCR instrument platform, offering researchers a wider range of reagent choices to implement on their existing instrumentation.

“Illumina’s qPCR portfolio adds tremendous value to our existing PCR solutions portfolio,” said Bill Molnar, Vice President of Category Management, Life Sciences, VWR. “Both of our companies are committed to enabling the world’s scientists to accelerate research. The addition of the Eco System and NuPCR reagents provides an essential element to our product line, empowering us to effectively support key customer segments.”

Customer orders for Illumina’s qPCR portfolio through VWR will be accepted starting December 1, 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ArcherDX, Illumina Launch Collaboration
Agreement to bring multiple Archer® assays through the FDA approval process.
Tuesday, May 31, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Berry, Illumina Co-Develop NGS System for CFDA Review and Approval
Berry Genomics will use Illumina’s NGS technology to secure Chinese Food and Drug Administration regulatory approval for clinical applications, expanding access to NGS-based tests in China.
Monday, July 21, 2014
Project Lays Foundation for Genomic Medicine
The University of Cambridge, Genomics England Ltd. and Illumina collaborate to sequence 10,000 whole human genomes for NHS patients.
Monday, October 21, 2013
Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012
Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011.
Tuesday, January 29, 2013
Scientific News
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Measuring the Abundance of Extremely Rare Mutations
Researchers from Rutgers University demonstrate the use of multiplex real-time PCR assays to measure the abundance of extremely rare mutations associated with cancer.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Finding Zika One Paper Disc At A Time
A novel, inexpensive method for detecting the Zika virus could help slow spread of outbreak, and potentially other future pandemic diseases.
Rapid Diagnosis of Bacterial Infections
Mass. General-developed compact system could shorten diagnostic time from days to hours, bring testing to point of care.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!